Vical Inc: All Recent News

• All recent news
• Earnings news

Vical Announces News Release and Conference Call Schedule for... 2/4/2010

SAN DIEGO, Feb. 4, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and twelve months ended December 31, 2009, before the opening of trading on Thursday, February 11, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, February 11. The call is open on a listen-only basis to any interested parties. The company will provide details on independent and partnered development programs in the conference call and webcast. GlobeNewswire

Eastman Kodak, Preferred Bank: Early Volume Plays 1/28/2010

Several stocks trading near $5 were poised to move on above-average volume during Thursday's session. At TheStreet.com

Vical Completes Enrollment in Allovectin-7(r) Phase 3 Trial... 1/28/2010

SAN DIEGO, Jan. 28, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company has completed enrollment of the planned 375 subjects in its multinational Phase 3 trial of Allovectin-7(R) in patients with metastatic melanoma. Allovectin-7(R) is a novel gene-based immunotherapeutic with a unique mechanism of action that is fundamentally different from currently approved treatments, and has the potential to be the first new primary treatment approved for metastatic melanoma in nearly 20 years. GlobeNewswire

Vical Updates Vaccine Development Programs for CMV and... 1/26/2010

WASHINGTON, Jan. 26, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company will present an overview of its DNA vaccine and adjuvant technologies and an update on its clinical-stage vaccine development programs at the Phacilitate Vaccine Forum (Washington - January 25-27). Alain P. Rolland, Pharm.D., Ph.D., Vical's Executive Vice President of Product Development, is scheduled to present on Wednesday, January 27, at 12:55 p.m. GlobeNewswire

Vical Names Richard T. Kenney, M.D., Vice President of... 1/14/2010

SAN DIEGO, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the appointment of Richard T. Kenney, M.D., as Vice President, Clinical Development. GlobeNewswire

Vical partner gets approval on artery drug study 1/12/2010

SAN DIEGO (AP) - Vical Inc. said Tuesday its partner AnGes MG Inc. has agreed with regulators on the design of a late stage trial of the drug Collategene, which is intended to treat artery disease by stimulating the growth of new blood vessels. Associated Press

UPDATE 1-Vical says PAD drug gets nod for late stage trial 1/12/2010

... At Thomson Reuters

Vical Licensee AnGes MG Reaches Agreement With FDA For Phase 3... 1/12/2010

SAN DIEGO, Jan. 12, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's licensee, AnGes MG, Inc., reported approval by the U.S. Food and Drug Administration (FDA) of the Special Protocol Assessment (SPA) agreement for a Phase 3 clinical trial of its Collategene(TM) angiogenesis product for patients with advanced peripheral arterial disease (PAD). The study will be multinational, randomized and placebo-controlled with a target population of 560 patients. GlobeNewswire

Vical says gov't clears melanoma vaccine for dogs 1/11/2010

SAN DIEGO (AP) - Drug developer Vical Inc. said Monday the Agriculture Department approved Oncept, a vaccine intended to treat oral melanoma in dogs. Associated Press

Vical Announces Licensee's Approval of ONCEPT(TM) Therapeutic... 1/11/2010

SAN DIEGO, Jan. 11, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the U.S. Department of Agriculture (USDA) has granted the company's licensee Merial Limited, the animal health subsidiary of sanofi-aventis, full licensure for its ONCEPT(TM) canine melanoma vaccine, a therapeutic DNA vaccine designed to aid in extending survival of dogs with oral melanoma. Merial plans to launch the product at the North American Veterinary Conference (Orlando, January 16 - 20). GlobeNewswire

Vical Secures $25 Million Issuer Managed Equity Facility With... 1/8/2010

SAN DIEGO, Jan. 8, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has secured an issuer managed equity facility under which it may sell up to $25 million of its registered common stock to Azimuth Opportunity, Ltd. Vical is not obligated to use any of the facility. GlobeNewswire

Mechanism of Action for Vical's Vaxfectin(R) Adjuvant Expands... 1/7/2010

SAN DIEGO, Jan. 7, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that systematic in vivo testing of the company's Vaxfectin(R) adjuvant shows that it increased antibody and T-cell responses primarily by stimulating the immune system rather than simply increasing vaccine uptake. The results, published in the journal Vaccine(1), validate encouraging results with the Vaxfectin(R) adjuvant in prior animal and human studies, and position Vaxfectin(R) as a potential "universal" adjuvant for a broad range of vaccines. GlobeNewswire

More News

Market Report

News by Symbol

Today's Investing Articles

Breaking News

News by Topic

News by Industry

MSNBC News

MSN Money

Search MSN Money

Message Boards

Site Status